Skip to main content
AARD
NASDAQ Life Sciences

心脏安全问题导致阿德瓦克公司的普拉德威利综合征III期试验暂停

feedReported by GlobeNewswire
Sentiment info
Negative
Importance info
9
Price
$12.49
Mkt Cap
$271.948M
52W Low
$4.88
52W High
$17.94
Market data snapshot near publication time

summarizeSummary

阿德瓦克治疗公司（Aardvark Therapeutics）自愿暂停了其III期英雄试验（HERO trial），该试验是针对普拉德威利综合征（Prader-Willi Syndrome）的首要化合物ARD-101的试验。暂停的原因是，在对健康志愿者的常规安全监测期间，发现了可逆的心脏观察结果。这一重大挫折为这家临床阶段生物制药公司带来了巨大的不确定性和延迟，因为ARD-101是关键的产品线资产。该公司将进行全面数据审查，并且不再预计在2026年第三季度宣布主要数据，预计在2026年第二季度提供进一步的指导。交易者将密切关注数据审查结果和任何修订后的开发计划，因为这个晚期项目的可行性现在受到质疑，可能会影响公司的估值。

在该公告发布时，AARD的交易价格为$12.49，交易所为NASDAQ，所属行业为Life Sciences，市值约为$2.7亿。 52周交易区间为$4.88至$17.94。 这则新闻被评估为消极市场情绪，重要性评分为9/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed AARD - Latest Insights

AARD
Apr 03, 2026, 4:05 PM EDT
Filing Type: 424B5
Importance Score:
9
Aardvark Therapeutics Activates $150M At-The-Market Offering, Signaling Massive Potential Dilution Amidst Trial Pause
Sentiment: Negative
View Wiseek Article
AARD
Mar 23, 2026, 6:30 PM EDT
Filing Type: 8-K
Importance Score:
9
Aardvark Therapeutics Establishes $150M ATM Program Amidst Trial Pause, Signaling Significant Dilution
Sentiment: Negative
View Wiseek Article
AARD
Mar 23, 2026, 5:10 PM EDT
Filing Type: S-3
Importance Score:
9
Aardvark Therapeutics Files $400M Universal Shelf, Including $150M ATM Offering, Amidst Phase 3 Trial Pause
Sentiment: Negative
View Wiseek Article
AARD
Mar 23, 2026, 4:45 PM EDT
Source: Reuters
Importance Score:
8
Aardvark Therapeutics Reports Q4/FY25 Results, Provides Business Updates Following Phase 3 Trial Pause
Sentiment: Neutral
View Wiseek Article
AARD
Mar 23, 2026, 4:19 PM EDT
Filing Type: 10-K
Importance Score:
9
Aardvark Therapeutics Halts All Lead Clinical Trials Due to Cardiac Safety Concerns, Delays Key Data
Sentiment: Negative
View Wiseek Article
AARD
Mar 23, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
9
Aardvark Pauses Phase 3 Trials for ARD-101 Due to Cardiac Safety Concerns; Provides Q4/FY25 Financials
Sentiment: Negative
View Wiseek Article
AARD
Mar 23, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
9
Aardvark Therapeutics Pauses Lead Phase 3 Drug Trial Over Cardiac Safety Signals
Sentiment: Negative
View Wiseek Article
AARD
Feb 27, 2026, 4:27 PM EST
Filing Type: 8-K
Importance Score:
9
Aardvark Therapeutics Pauses Key Phase 3 Trial for ARD-101 Due to Cardiac Safety Observations
Sentiment: Negative
View Wiseek Article
AARD
Feb 27, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
9
Cardiac Safety Concerns Halt Aardvark's Phase 3 Prader-Willi Trial
Sentiment: Negative
View Wiseek Article
AARD
Feb 12, 2026, 8:17 AM EST
Filing Type: 8-K
Importance Score:
8
Aardvark Therapeutics Establishes Dermatology Subsidiary, Appoints CEO, and Expands Executive Team
Sentiment: Positive
View Wiseek Article